invest to develop a more professional structure
enhance management, administration, coordination & communications
build a more efficient, integrated organisation & team approach
increase precision in stratification, treatment & disease monitoring
improve molecular characterisation & extend biomarker research
pursue targeted agents, immunotherapies & combination therapies
renew focus on education, training & mentorship
increase involvement of early-career researchers
retain talent & develop new leadership potential
streamline & standardise operational elements
build capability to deliver & open trials more quickly & efficiently
develop & deliver studies for high-risk, non-high-risk & relapse patients
enhance collaboration with other research networks including ITCC & COG
build engagement strategies for regulatory agencies & pharma companies
increase engagement & involvement of advocates
implement fit-for-purpose infrastructure to efficiently collect & store data
build core data dictionary & standardise terminology across trials
increase involvement of statisticians + collaboration with other groups
